Balyasny Asset Management’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Balyasny Asset Management’s Portfolio NBP Stock Details NBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50,247	Closed	-$568K	–	3029
2022 Q2	$568K	Buy	+50,247	New	+$602K	﹤0.01%	1935
2021 Q4	–	Sell	-3,000	Closed	-$217K	–	2409
2021 Q3	$217K	Buy	+3,000	New	+$217K	﹤0.01%	1637
2021 Q2	–	Sell	-25,731	Closed	-$1.25M	–	2142
2021 Q1	$1.25M	Buy	+25,731	New	+$1.4M	0.01%	1177

Other funds holding NBP

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cederberg Capital London, United Kingdom $186M AUM 21.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's NBP Position: Q3 2022 in Review

Balyasny Asset Management sold out of NovaBridge Biosciences American Depositary Shares (NBP) in Q3 2022, closing a stake of 50,247 shares — an estimated $568K sold.

Balyasny Asset Management first reported a position in NBP in Q1 2021 and held it in 3 quarters. The position peaked at $1.25M in Q1 2021. 75 funds tracked by Wall St. Rank hold NBP as of Q3 2022.

Balyasny Asset Management reported no remaining NovaBridge Biosciences American Depositary Shares position as of Q3 2022 after selling out during the quarter.
Balyasny Asset Management sold 50,247 NovaBridge Biosciences American Depositary Shares shares in Q3 2022, an estimated $568K.
Balyasny Asset Management first reported a position in NovaBridge Biosciences American Depositary Shares in Q1 2021 and held it in 3 quarters.
Balyasny Asset Management's NovaBridge Biosciences American Depositary Shares position peaked at $1.25M in Q1 2021.
75 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.